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Abstract 
A previously described equation using the free energy of water desolvation (ΔGdesolv,CDS),  the 
lipophilicity free energy (ΔGlipo,CDS), dipole moment and molecular volume that describes the 
ability of drugs to cross the blood brain barrier and other cell membranes has been shown to 
apply to transdermal permeation when combined with ultrasound treatment. The dipole moment 
is particularly important when seeking to predict how drugs will interact with the transient pores 
in the cell membrane or blood brain barrier under ultrasound treatment. 
 
A quantum mechanical DFT analysis of the molecular interaction of mannitol and BCNU 
interacting with a surrogate membrane based on DPhPC has shown that the unexpected greater 
US induced permeability of mannitol compared to BCNU is due to differences in how the 
dipoles of mannitol and BCNU interact with the electric dipole potential of the lipid bilayers of 
the blood brain barrier, specifically by interacting with the phosphatidylcholine headgroup not 
the ester group. This result indicates that the design of therapeutic drugs to cross dermal and 
BBB membranes should consider whether such drugs can interact with the phosphatidylcholine 
headgroup of the membranes thereby possibly lowering the dipole potential of the lipid bilayer 
and hence enhancing drug permeation. 
 
The observed increase in electrical conductivity of the stratium corneum of the skin and blood 
brain barrier upon ultrasound treatment is an important factor which determines the transient 
permeabilization enhancement of drugs. It is likely that the dipole moment of permeating drugs 
may be a critically important factor that interacts with the membrane dipole potential of the 
stratium corneum of the skin and blood brain barrier upon ultrasound treatment. Transient pores 
are known to be involved when electrical fields are exerted on biological membranes, with 
conductance spikes occurring during the opening and closing of these transient pores. The 
opening and closing of lipidic pores also involve electrically invisible (silent) pre-pores.  
 
 
Introduction 
The use of therapeutic ultrasound to enhance the transport of drugs through biological tissue is 
well established. Conventional drug delivery (not associated with a carrier system) by systemic 
intravenous injection, topical application, and oral means can be enhanced by ultrasonic 
techniques. Sustained release formulations of drugs, such as micelles and liposomes, which can 
sequester drugs in their lipophilic membranes or hydrophilic aqueous cores) (liposomes) or 
lipophilic cores (micelles) have also shown enhanced transport with ultrasound (US). Focussed 
US using pulsing techniques can be advantageous because it uses lower power preventing tissue 
damage or necrosis. It has been shown that US increases the permeability of cell membranes by 
creating transient holes in the membrane as a result of acoustic cavitation events, thereby 
facilitating drug transport. [1-3] 
Sonoporation is the general term for the use of US with microbubble mediated cavitation to 
generate transient pores in the walls of blood vessels to enhance drug deliverability. 
Microbubbles are gas filled bubbles stabilized by a surfactant such as a protein or polymer at 
their surface. Drugs can be loaded onto the shell or into the void of the microbubble, and surface 
modification can allow specific binding to cells at a target site. Application of US triggers the 
release of drugs at the target site.  
 
Drug deliverability can be triggered by stable cavitation (where microbubbles oscillate without 
collapsing in an acoustic field) or inertial cavitation of microbubbles (where microbubbles  
collapse in field causing secondary mechanical effects). Stable and inertial cavitation exert 
mechanical forces on adjacent tissues. Cell membrane permeabilizations caused by acoustic 
cavitation are considered reversible and cell membranes usually return to their original 
conformation quickly. Several microbubble formulations are already FDA approved, and many 
others are in clinical trials. Sonoporation relies on ultrasonic parameters such as acoustic 
pressure, pulse length, duty cycle, repetition rate, and exposure duration, as well as microbubble 
properties such as size, gas species, shell material, interfacial tension, and surface rigidity. 
Lower US frequencies produce better therapeutic outcomes because of reduced attenuation and 
deeper tissue penetration. [1-4] 
 
The FDA has recently approved the use of focussed US (FUS), guided by magnetic-resonance 
imaging, to concentrate sound waves on a specific spot in a patient’s head to treat Parkinson 
disease. The FDA has also recently approved a clinical trial specifically aimed at temporarily 
disrupting the blood brain barrier (BBB) without causing tissue damage, with the ultimate aim of 
dramatically enhancing the ability of clinicians to treat brain diseases since the vast majority of 
drugs cannot permeate the BBB. The trial involves injecting microscopic inert gas-filled bubbles 
into a patient's bloodstream and then oscillating the microbubbles with highly targeted pulsed US 
waves, thus stretching the brain blood vessel walls to create temporary openings, lasting about 
four to six hours. 
Ultrasonic drug delivery has been widely studied and therapeutic agents such as genetic material, 
proteins and chemotherapeutic agents have shown that the use of microbubbles enormously 
enhances their delivery. Attaching the genetic material such as DNA or drugs directly to the 
microbubbles or to gas-containing liposomes enhances gene uptake even further enhances uptake 
in tissues such as cardiac, vascular, skeletal muscle, tumor and fetal tissue. US enhanced 
transdermal delivery of insulin and other proteins and hormones result from the reversible 
disruption of the structure of the stratus corneum. Drugs can also be delivered utilizing 
microbubbles, micelles and liposomes carriers, whereby the cavitation can disrupt the carrier 
vesicle and release the drug, as well as permeabilizing cell membranes and blood capillaries. [1-
5] The permeabilization of cell membranes caused by sonoporation using microbubbles has been 
shown to involve endocytosis as well as other mechanisms driven by acoustic pressure.  
 
The therapeutic delivery of drugs using US can be achieved by using (a) the free drug with US, 
(b) the free drug co-administered with US and microbubbles, or (c) using drug impregnated 
microbubbles with US. Both (a) and (b) suffer from lack of direct targeting the desired tissue, 
whereas (c) can target specific tissue by tailoring the microbubble surface to allow specific 
binding to cells at a target site. However pursuing clinical trials and obtaining approval for (c) ie 
therapeutic regimens and FDA approval for specific tailored microbubbles with US protocols 
will be a far more demanding route to clinical use than those required for (a) or (b) where 
approved drugs and approved microbubbles can be used with an approved US protocol. 
 
The BBB represents a formidable challenge to therapeutic treatment of brain diseases. Following 
US BBB disruption it’s possible to deliver therapeutics including small molecules, nanoparticles, 
liposomes and even stem cells. Sonication has been used to open the BBB in mice, to deliver 
antibodies to alpha synuclein, a protein that occurs in patients with Parkinson’s disease, resulting 
in enhanced antibody delivery, reduction of alpha synuclein levels and a change in the animals’ 
symptoms. The antibody is several hundred times the size of typical Parkinson’s disease drugs. 
[6] 
 
However, while there has been extensive research and trials of US enhanced drug delivery in 
various cells and tissues, there is little known about what are the particular characteristics of 
various drugs that can show enhanced drug delivery. Since cavitating gas bodies such as 
oscillating gas bubbles or microbubbles are critical factors in drug delivery efficacy, clearly the 
interaction of drugs with the gas bubbles or gas containing microbubbles and their release upon 
sonication becomes a crucial factor in predicting US enhanced drug delivery and efficacy. 
Changes to the permeability of tissues and capillaries upon US treatment have been well 
characterized, but the characteristics of the therapeutic drug and interaction with the disrupted 
cell membranes has not been well addressed, other than molecular weight (size) of the drug 
being a significant factor.  
 
This study aims to: 
(1) Evaluate what are the molecular properties of drugs that determine their permeability of cell 
membranes, particularly in the skin and BBB. 
(2) Evaluate how US permeabilizes cell membranes and whether a previous documented model 
of the ability of drugs to cross cell membranes and the BBB can be used to predict what 
drugs can more easily cross cell membranes and the BBB after US treatment.  
 
Results 
 
This section analyzes available systematic data for the deliverability of various drugs and 
molecules across the skin or BBB from literature sources, in sections (a) to (c) below, and then 
analyzes that data (in d) using a model we previously developed that can accurately describe how 
various drug molecular properties determine the permeability of these drugs to cross cell 
membranes and the BBB. 
 
(a) Delivery of encapsulated drugs using FUS microbubble techniques 
 
Konofagou at al [9-11] have shown that drugs could potentially be impregnated into the lipid 
coating of microbubbles and then released at the blood brain barrier near pulsed focussed US 
induced BBB openings that allow various drugs to be transported across the BBB. FUS is 
focussed on specific regions of the brain, where the microbubbles oscillate and increase in size 
(up to a critical 8 micron size) and result in openings in the BBB. The acoustic pressure appears 
to be the driving force for the microbubble activity.  
 
The delivery of some large molecules has been demonstrated using FUS with microbubbles, 
including MRI contrast agents such as Omniscan (573 Da), Evans Blue (961Da), Herceptin (148 
kDa), doxorubicin (544 Da), and rabbit anti-Ab antibodies. FUS with microbubbles was shown 
to allow molecules up to 2000 Da to cross the BBB. [8-9] In particular, Dextrans of 3,10 and 
70kDa crossed the BBB, with the 3 kDa dextran having greater permeability. The 10 kDa 
dextran showed similar permeability as the 3 kDa dextran, but with less homogenous 
concentrated diffusion. However, 70 kDa dextran showed numerous punctuated regions of 
higher concentration, indicating a more heterogeneous overall distribution than the 3 and 10 kDa 
dextran, suggesting that drug molecular factors other than molecular size determined the in vivo 
FUS microbubble induced permeability. [11,12] 
 
The use of various FUS microbubble preclinical techniques to enhance drug delivery to the brain 
has been reviewed, and includes multifunctional theranostic multibubbles with FUS-induced 
BBB opening to treat brain tumours. For example the use of BCNU impregnated microbubbles 
with FUS to treat brain glioma in rats has shown  a 12% increase in efficacy compared to BCNU 
alone, but also lowered BCNU disposition in the liver by 4.8 fold, demonstrating the lower side 
effect toxicity of the microbubble encapsulation. [13] 
 
(b) Transdermal delivery of free drugs using US techniques 
 
The use of US to enhance the transdermal delivery of drugs (sonophoresis) is a well established 
method. [1-5] Mitragotri et al [14-17] have systematically investigated how some common drugs 
and molecules show enhanced transdermal permeability. Using therapeutic US techniques (1 
MHz, 1 W/cm2) the permeability of benzene, butanol, caffeine, corticosteroid, estradiol, 
progesterone, testosterone was studied. Using a pulsed low frequency US method (20-100 kHz, 
0.84 W/cm2), aldosterone, butanol, salicyclic acid, corticosterone, estradiol, sucrose, and water 
were also examined. The strong dependence on US frequency was attributed to cavitation 
effects. At a given intensity, the enhancement decreased with increasing ultrasound frequency. 
An increase in homogeneity of transport was noticed with increased frequency, with the 
maximum around 60 kHz. Generally low frequency US enhances transdermal permeation by up 
to 1000 times higher than that induced by therapeutic US. [14-17] 
 
The stratium corneum (SC) of the skin was identified as the skin layer showing US enhanced 
permeability. A 30% decrease in skin electrical resistance was a notable effect directly related to 
the enhanced transdermal permeability. [14-17]  
 
(c) Delivery of free drugs across the BBB using US techniques 
 
Liu et al [18] have examined how water, mannitol, BCNU, inulin (5kDa), dextran (70 KDa) and 
gd-lipo can be transported across the BBB of porcine brain tissue under US conditions. The 
degree of permeability enhancement was strongly dependent on US parameters, increasing 
proportionally with the energy density, duty cycle and inversely with the frequency at a given 
energy. US at frequencies of 85 kHz, 174 kHz, and 1 MHz enhanced the in vitro permeation of 
tritium labeled molecules across porcine brain tissue. A maximum enhancement of 24-fold was 
observed at 85 kHz and 1,200 J/cm2. Drug delivery in vivo exposure in the brain of a non-human 
primate to 1-MHz ultrasound was also shown not to cause any detectable damage. A rough 
relationship exists between the enhancement in permeability under US and the molecular weight 
of the transported drugs. The BBB permeability of dextrans of 3,10 and 70kDa showed 
molecular factors other than just molecular size determined the in vivo FUS microbubble 
induced permeability. [11,12] 
A linear relationship between BBB permeability enhancement and electrical membrane 
conductivity enhancement for mannitol was observed for all of the frequencies and energy 
densities. [18] 
 
A comparison of the permeability of mannitol and the brain cancer drug BCNU in porcine brain 
tissue showed that despite the large molecular differences between mannitol and BCNU, and the 
difference in passive permeability (3.51 x 10-6 and 1.9 x 10-6 cm/min respectively) the relative 
enhancement under US of mannitol was significantly greater than that of BCNU. [18] 
 
(d) A model to predict the permeation of drugs across cell membranes and the blood brain 
barrier 
 
We have previously developed a four parameter model that has been shown to apply to the 
transport and anti-cancer and metabolic efficacy of various drugs. The model, equation 1, is 
based on establishing linear free energy relationships between the four drug properties and 
various biological processes. Equation 1 has been previously applied to passive and facilitated 
diffusion of a wide range of drugs crossing the BBB, the active competitive transport of tyrosine 
kinase inhibitors by the hOCT3, OATP1A2 and OCT1 transporters, and cyclin-dependent kinase 
inhibitors and HIV-1 protease inhibitors.  The model also applies to PARP inhibitors, the anti-
bacterial and anti-malarial properties of fluoroquinolones, and active organic anion transporter 
drug membrane transport, and some competitive statin-CYP enzyme binding processes. There is 
strong independent evidence from the literature that ΔGdesolvation, ΔGlipophilicity, the dipole moment 
and molecular volume are good inherent indicators of the transport or binding ability of drugs. 
[19-28] 
 
Equation 1: 
Transport or Binding = ΔGdesolvation + ΔGlipophilicity + Dipole Moment + Molecular Volume  
Or eq 1(a) 
Transport or Binding = ΔGdesolv,CDS + ΔGlipo,CDS + Dipole Moment + Molecular Volume  
 
A modified form of equation 1, eq 1(a), using the free energy of water desolvation (ΔGdesolv,CDS) 
and the lipophilicity free energy (ΔGlipo,CDS) where CDS represents the non-electrostatic first 
solvation shell solvent properties, may be a better approximation of the cybotactic environment 
around the drug approaching or within the protein receptor pocket, or the cell membrane surface 
or the surface of a drug transporter, than the bulk water environment outside the receptor pocket 
or cell membrane surface. The CDS includes dispersion, cavitation, and covalent components of 
hydrogen bonding, and hydrophobic effects. Desolvation of water from the drug (ΔGdesolv,CDS) 
before binding in the receptor pocket is required, and hydrophobic interactions between the drug 
and protein (ΔGlipo,CDS) is a positive contribution to binding. ΔGlipo,CDS is calculated from the 
solvation energy in n-octane. We have previously shown that ΔGlipo,CDS is highly linearly 
correlated with log P, the octanol-water partition coefficient. [22] In some processes, the 
influence of some of the independent variables is small and can be eliminated to focus on the 
major determinants of biological activity.  
The deliverability of molecules across SC of the skin [14-17] and the BBB [18] as shown in 
Table 1has been analyzed by the general equation 1(a). The data sets for the molecular properties 
have been normalized (by dividing the calculated molecular volumes in water by a factor of 20) 
to allow direct comparison of the coefficients of the independent variables. While the statistical 
significance of some of the equations is low, the object is to directly compare the effect of US 
treatment on a small number of the same drugs by comparing the ratios and signs of the four 
independent variables.  
 
Transdermal Permeability (TP1): benzene, butanol, caffeine, corticosteroid, estradiol, 
progesterone, testosterone                                                                           Equation 2(a) 
TP1 = -118.7ΔGdesolv,CDS - 0.75ΔGlipo,CDS - 50.7Dipole Moment – 32.8Molec Vol - 83.1 
Where R2  = 0.701, SEE = 56.1, SE(ΔGdesolvCDS) = 89.3, SE(ΔGlipoCDS) = 21.2, SE(Dipole Moment) = 31.6, SE(MV) = 27.0, 
F=1.17, Significance=0.51 
 
Therapeutic US Enhanced Transdermal Permeability (TUSTP): benzene, butanol, caffeine, 
corticosteroid, estradiol, progesterone, testosterone                                     Equation 2(b) 
TUSTP = 6.75ΔGdesolv,CDS - 0.92ΔGlipo,CDS + 1.05Dipole Moment + 2.52Molec Vol + 7.1 
Where R2  = 0.554, SEE = 5.04, SE(ΔGdesolvCDS) = 8.06, SE(ΔGlipoCDS) = 1.90, SE(Dipole Moment) = 2.83, SE(MV) = 2.42, 
F=0.62, Significance=0.69 
 
Comparison of the DM/ΔGlipo,CDS, MV/ΔGlipo,CDS and ΔGdesolv,CDS/ΔGlipo,CDS ratios in eq 2(a) and 
eq 2(b) show that transdermal permeation is dominantly negatively dependent upon DM, MV 
and ΔGdesolv,CDS whereas when therapeutic US is used to increase permeability, DM, MV and 
ΔGdesolv,CDS have about the same positive importance as lipophilicity of the drugs in this data set. 
However, the low statistical precision of eq 2(a) and 2(b) means that these comparisons are only 
indicative. These observations are consistent with a major mechanistic change in the dermal 
permeability upon US. 
 
Transdermal Permeability (TP2): aldosterone, butanol, salicyclic acid, corticosteroid, estradiol, 
sucrose, water                                                                                                Equation 3(a) 
TP2 = 0.91ΔGdesolv,CDS - 1.07ΔGlipo,CDS - 0.20Dipole Moment - 0.10Molec Vol + 2.14 
Where R2  = 0.558, SEE = 0.81, SE(ΔGdesolvCDS) = 0.41, SE(ΔGlipoCDS) = 0.45, SE(Dipole Moment) = 0.17, SE(MV) = 0.28, 
F=2.89, Significance=0.27 
 
Low Frequency US Transdermal Permeability (LFUSTP): aldosterone, butanol, salicyclic acid, 
corticosteroid, estradiol, sucrose, water                                                           Equation 3(b) 
LFUSTP = -950.3ΔGdesolv,CDS + 1174.3ΔGlipo,CDS - 500.8Dipole Moment + 558.8Molec Vol -
56.2 
Where R2  = 0.862, SEE = 679.6, SE(ΔGdesolvCDS) = 344.3, SE(ΔGlipoCDS) = 376.1, SE(Dipole Moment) = 143.4, SE(MV) = 24.1, 
F=10.37, Significance=0.088 
 
Eq 3(a) and (b) use a different set of drugs from those used in eq 2(a) and (b), and contain more 
hydrophilic drugs (salicylic acid, sucrose, water). Comparison of the DM/ΔGlipo,CDS, 
MV/ΔGlipo,CDS and ΔGdesolv,CDS/ΔGlipo,CDS ratios in eq 3(a) and eq 3(b) show that transdermal 
permeation is dominantly negatively dependent upon DM and MV, but positively dependent 
upon  ΔGdesolv,CDS. However when low frequency US is used to increase permeability, DM and 
ΔGdesolv,CDS have about the same negative importance as lipophilicity of the drugs in this data set, 
but MV has a positive importance compared to lipophilicity. These observations possibly 
indicate that low frequency US dermal permeability could involve different changes to the 
dermal SC compared to therapeutic US as used in eq 2(b) or alternatively a result of the greater 
number of hydrophilic drugs in the data set used for eq 3(b). 
 
Unfortunately there is little available systematic drug data from investigations of the US 
enhanced permeability of the BBB. However, a direct comparison of BBB permeabilities of 
mannitol and BCNU is available, [18] and the molecular properties have been calculated. (see 
Table 1). Assuming eq 1(a) describes the BBB permeability of these drugs, then it appears that 
the greater permeability of mannitol is attributed to its lower lipophilicity (ΔGlipo,CDS -3.34 
compared to -4.44 for BCNU) since the ΔGdesolv,CDS, DM and MV are essentially the same for 
both. The similarity in drug water desolvation for mannitol and BCNU suggest that transport 
paths across the BBB are not aqueous in nature, but dominated by hydrophobic mechanisms. It is 
noted that mannitol has a greater permeability than BCNU under both passive and US enhanced 
conditions. 
 
There is clear evidence that molecular weight (or MV) strongly influences BBB permeability as 
can be seen for dextran (70kDa) and inulin (5kDa) in Table 1, particularly since comparison of 
the notional C12 oligomer units for these biopolymers show similar ΔGdesolv,CDS, ΔGlipo,CDS, DM 
and MV values, indicating that overall molecular size of the biopolymers is the dominant 
determining factor in permeability.  
 
Discussion 
 
An important observation in US enhanced permeability of dermal and BBB membranes is the 
observation that increased permeability is accompanied by increased electrical conductivity of 
the membranes. [14-18] Any mechanism that deals with how drug transport can be enhanced by 
US must account for this seminal observation. Reversible and irreversible membrane US 
permeabilization is postulated to be related to the number of transient cavitation events. [29] It is 
also known that electrical fields promote pore formation in biological membranes, and 
conductance spikes were associated with the opening and closing of transient pores. The opening 
and closing of lipidic pores also involve electrically invisible (silent) pre-pores. [30] It is then 
conceivable that US induced permeabilization of dermal and BBB membranes involves transient 
and reversible US induced cavitation-electrical polarization of membranes. The typical 
biological cell membrane has a electrical potential between the inside and outside of the cell of 
about -40 to -80 mV. The cell membrane (a phospolipid protein bilayer) is a dielectric with a 
dielectric constant of ca 9. Hence US cavitation events can disrupt the cell bilayer and induce 
changes to the membrane electrical potential.  
 
The total electrical potential across a cellular lipid membrane consists of (a) the transmembrane 
potential due to differences in the salt concentrations on both sides of the membrane, (b) the 
surface potential due to the charged head groups of the phospholipid molecules and the attracted 
ions that accumulate at the surface of the membrane, (c) The dipole potential comprised of a few 
dipole potentials within and on the surface of the membrane. The dipole potential is the largest 
dominant component of membrane electric field strength. [32,33] 
 
The dipole potential of a lipid bilayer consists of phospholipid carbonyls in the head group 
regions of the bilayer, the ester linkage between the head group and the fatty acid chains and the 
terminal end of the fatty acid chain. Layers of structured water are also attached to the surface of 
the bilayer, resulting in orientation of the water dipoles. The zwitterionic (P- - N+) 
phosphatidylcholine lipid head group carries charges, and are notionally electrical neutral. The 
influence of molecules interacting with the lipid bilayer and changing the membrane dipole 
potential depends on how these molecules interact with the lipid bilayer: for example the 
orientation and strength of the interaction with the phospholipid carbonyls in the head groups, or 
with the ester linkage or the terminal ends of the fatty acid chains will have dramatically 
different effects on the dipole potential. [19,31,32,33] The dipole moment of the permeating 
drugs will depend on their particular molecular structures.  
 
Electrical fields have been shown to promote pore formation in biological membranes, and 
particularly conductance spikes are associated with the opening and closing of transient pores. 
The opening and closing of lipidic pores also involve electrically invisible (silent) pre-pores. [30] 
So the dynamic interaction of the dipole of various drugs interacting with the cell membrane 
under US can lead to changes in the membrane dipole potential to create transient pores to allow 
enhanced drug permeation across the cell membrane. In the absence of a drug, US induced 
transient pores can still be created in the cell membrane, but the membrane dipole potential 
would differ from that which would exist when the drug was present (and interacting with the 
lipid bilayer via its dipole moment).  
 
Transport of drugs and molecules across cell membranes must involve interaction with the 
membrane potential. Eq 1 and 1(a) include the dipole moment (DM) of the drug as one of the 
important factors that govern permeability of drugs across the cell membrane and the BBB. [19] 
 
It is noted that only eq 3(b) LFUSTP has significant statistical precision to make any conclusions 
about what drug molecular properties influence US enhanced dermal permeability. Eq 2(b) is 
similar to that of eq 3(b) but the low precision for therapeutic US precludes direct comparison 
with the low frequency US used in 3(b). 
 
Eqs 3(b) for the LFUSTP  shows that the enhanced SC permeation is negatively influenced by 
the DM and desolvation ΔGdesolv,CDS of the drugs but positively influenced by the lipophilicity 
ΔGlipo,CDS and MV. Eq 3(a) for TP2 shows that permeation is negatively influenced by 
lipophilicity, and to a lesser extent DM and MV, but positively dependent upon desolvation of 
the drugs. So US treatment has a dramatic effect on the SC permeation particularly influenced by 
the lipophilicity and desolvation of the drugs. The positive effect of MV under US conditions 
suggests that US induced membrane pores are large enough to allow easy passage of the drugs 
tested, ie there is no steric impediments to passage through the formed lipid pores, particularly 
for low < 500 MW drugs. [4,16] It has been reported that drugs (such as 6-ketostanol) whose 
structures possess a large molecular DM can modulate the dermal membrane dipole potential 
resulting in enhanced dermal delivery of certain drugs (such as bacitracin). [43]  
 
The negative dependency of the LFUSTP on water desolvation of the drugs (eq 3b) indicates that 
it is permeation of the lipid bilayers that dominates transport across the membrane, and that 
desolvation of the drugs is required before they can permeate through the US produced pores in 
the lipid bilayers. 
 
The negative dependence upon the DM is consistent but becomes more important upon US 
treatment suggesting that increased electrical conductivity of the US treated membrane has a 
damping effect on permeability possibly caused by drug interaction lowering the membrane 
dipole potential. We have previously shown that the DM is a particularly important factor is 
determining the permeability of drugs in crossing the BBB, since the membrane dipole potential 
induces a strong electrical field in the lipid rafts of the cell membrane. [19,31] A recent analysis 
of the partitioning of a large variety of drugs in phospholipid microsomes has shown that for a 
large number of neutral drugs that the partitioning factor (ie the lipid binding constant times the 
lipid concentration), was strongly linearly related to log P, negatively related to DM, as well as 
the number of S=O and NO2 groups. [44] This literature result is consistent with the results in eq 
3(b). 
 
The US enhanced transport of the biomolecules (dextran 70kDa and inulin 5kDa) across the 
BBB has been shown to be dominated by MV (or molecular size) rather than desolvation, 
lipophilicty or DM, assuming that the notional C12 polymer units reflect the overall desolvation, 
lipophilicity and DM of the biopolymers. Certainly the data of Liu [18] indicated that the 
membrane pores created under their experimental conditions allowed the transport of even larger 
biomolecules such as the liposome gd-lipo, although endocytosis cannot be ruled out for these 
large liposomes. Mannitol has a greater BBB permeability than BCNU, though it has a lower 
lipophilicity (ΔGlipo,CDS -3.34 compared to -4.44 for BCNU, or comparing octanol-water partition 
coefficients of mannitol log P -3.1 to BCNU log P 1.5). The greater lipophilicity for BCNU 
would be expected to enhance permeability in membrane lipid bilayers over that found for 
mannitol. The ΔGdesolv,CDS, DM and MV are essentially the same for both. The similarity in water 
desolvation for mannitol and BCNU suggests that transport paths across the BBB are not 
aqueous in nature. Although the overall DM for both BCNU and mannitol are very similar, it is 
possible that their very different molecular structures could result in their dipoles interacting with 
the electrical dipole potential of the BBB in very different conformations, thus affecting the 
formation and properties of the US induced transient pores in the lipid bilayers.  
 
The branched-chain lipid diphytanoyl phosphatidylcholine, DPhPC, has been used to form robust 
well characterized artificial membranes. Using cryo electron microscopy (cryo-EM) and 
molecular dynamic modelling, the dipole potential of DPhPC phospolipid bilayer membranes in 
frozen liposomes has been calculated to be 510 mV. The main partial charges contributing to the 
dipole potential are labeled as + and - on one chain of each lipid as shown in Figure 1. It is 
known that negatively charged molecules diffuse across phospholipid membranes faster than 
positively charged molecules. This is thought to be due to a large positive electrostatic charged 
membrane interior. The size of this potential is thought to arise from the DM of the ester group 
of the phospholipid, and that the zwitterionic phosphatidylcholine headgroup has little effect on 
the membrane dipole potential. [34]  
 
In order to evaluate how evaluate how various drugs can interact with cellular phospolipid 
bilayer membranes in the BBB prior to or during drug permeation of the BBB, we have 
previously used DPhPC to compare possible interaction sites with phospolipid bilayers as 
surrogates for the BBB. We have previously shown [19] that the interaction of various drugs 
with the zwitterionic headgroup (prior to the drugs actually permeating into the lipid bilayer) can 
alter the membrane dipole potential, hence altering the permeability of the charged or neutral 
drugs to cross the cell membrane. It has been shown that stabilizing interactions of up to 3 
kcal/mol occurs as the drug moves from the bulk solvent to the phosphatidylcholine headgroup 
in the model phospholipid membranes (about 25-30 Å from the bilayer centre). The most 
stabilising region is about 10-15 Å from the bilayer centre, which reflects the hydrophobic 
stabilization as the drug penetrates the bilayer. [45] The contributions of the phosphatidylcholine 
headgroup, the acyl ester groups and water at the midpoint of the lipid bilayer of phospholipid 
membranes to the total membrane dipole potential have been calculated to be -1.21 kcal/mol (-
52.7mV), +0.26 kcal/mol (+11.5mV) and +0.4 kcal/mol (+17.5mV) respectively, with a large 
positive component (+mV) probably due to the water of hydration of the lipid bilayer accounting 
for the experimentally known large positive dipole potential of the membrane. [46] 
 
It is known that phosphatidylcholine type lipids have dipole moment between 18 to 25 D, 
comprised of  (a) the phosphatidylcholine headgroup contributing ca 6+/-3D with the dipole 
direction pointing towards the aqueous layer away from the bilayer interior (negative charge 
towards the interior) and the headgroup oriented more parallel than vertical to the lipid layer, (b) 
the carbonyl group of acyl chains (ca 2.5D), and (c) oriented water molecules next to the lipid 
bilayer (ca 1.8 D). Thus it is thought that it is the dipole moments of lipid bound water molecules 
which are responsible for the positive charge of the internal membrane dipole potential. [35-41] 
It has been shown that water molecules hydrogen bond with phosphatidylcholine type lipids 
mainly via mainly via the phosphate oxygen (ca 4 H bonds) and to a lesser extent  (ca 1 H bond) 
via the ester carbonyl group, including some bridging hydrogen bonds. [42] For neutral drugs, 
like mannitol and BCNU, hydrogen bonding with the oxygen atom of the phosphate group or the 
carbonyl ester group can alter the membrane or BBB dipole potential, thus altering the ease of 
other (second, third etc) molecules of the binding drugs to permeate the lipid bilayers. Figure 1 
shows the likely sites of drug interaction as being the negative phosphate group, the ester 
carbonyl group or the positively charged quaternary N group.  
 
The DM of DPhPC (or ester-DPhPC as shown in Figure 1) in water is 22.6D, with the dipole 
direction being directed from the negative phosphate group to the positively charged quaternary 
N group of the zwitterion. (Figure 2) The dipole potential of DPhPC is 510mV as measured 
experimentally by cryo-EM. The DM of the ether-DPhPC (as shown in Figure 1) in water has a 
DM of 26.2DM with the dipole direction being the same as the ester-DPhPC. The ether-DPhPC 
membrane has a dipole potential of 210mV, about half of that for the ester-DPhPC [34]. Hence it 
can be observed that lower dipole potential for an ether-DPhPC phospolipid bilayer membrane 
compared to an ester DPhPC phospolipid bilayer membranes results from the larger DM of the 
ether-DPhPC acting in the opposite direction to the positively charged inner lipid area of the 
phospholipids compared to that for the ester-DPhPC membrane. The large positive electrostatic 
potential in the interior of the membrane accounts for much of this permeability difference 
between the ether-DPhPC and ester-DPhPC membranes. [34] 
 
Hydrogen bonding interaction of a mannitol hydroxyl to the P—O group of DPhPC results in an 
overall dipole moment of 25.9D (Figure 3(a)). Comparing the hydrogen bonding of the N—H 
group of BCNU to the P—O group of DPhPC results in an overall DM of 21.3D (Fig 3(b)). The 
large change in DM when mannitol interacts with the P—O group compared to the interaction of 
BCNU with the P—O group (ca 4.6D) strongly indicates that mannitol will have a larger 
lowering on the dipole potential of a phospholipid membrane (compared to BCNU) and therefore 
resulting in an increased permeability for mannitol over that of BCNU in a cell membrane.  
Hydrogen bonding interaction of a mannitol hydroxyl to the ester C=O group of DPhPC results 
in an overall dipole moment of 23.2D (Figure 4(a)). Comparing the hydrogen bonding of the 
N—H group of BCNU to the C=O group of DPhPC results in an overall DM of 23.7D (Fig 4(b)). 
There is no change in DM when both drugs interact with the ester carbonyl suggesting that the 
dipole potential of a membrane interacting with these two drugs would not be significantly 
different. The DMs for the four complexes were essentially independent of the hydrogen bonding 
lengths in the range 2.0-3.0Å, and the water desolvation ΔGdesolv,CDS values were also the same 
within calculation error.  
In view of the experimentally observed greater permeability of mannitol over that of BCNU, 
these results suggests that both of these drugs do not significantly hydrogen bond to the ester 
moiety of a phospholipid membrane in the BBB. This observation is contrary to current beliefs 
where it is thought that the dipole of the ester group has a much larger influence on the dipole 
potential than that of the zwitterionic phosphatidylcholine headgroup. [34] 
 
Conclusions 
 
A previously described equation (eq 1 or 1(a)) using the free energy of water desolvation 
(ΔGdesolv,CDS),  the lipophilicity free energy (ΔGlipo,CDS), dipole moment and molecular volume 
that describes the ability of drugs to cross the blood brain barrier and other cell membranes has 
been shown to apply to transdermal permeation when combined with ultrasound treatment. The 
dipole moment is particularly important when seeking to predict how drugs will interact with the 
transient pores in the cell membrane or blood brain barrier under ultrasound treatment. 
 
A quantum mechanical DFT analysis of the molecular interaction of mannitol and BCNU 
interacting with a surrogate membrane based on DPhPC has shown that the unexpected greater 
US induced permeability of mannitol compared to BCNU is due to differences in how the 
dipoles of mannitol and BCNU interact with the electric dipole potential of the phospholipid 
bilayers of the blood brain barrier, specifically by interacting with the phosphatidylcholine 
headgroup, not the ester group. This result indicates that the design of therapeutic drugs to cross 
dermal and BBB membranes should consider whether such drugs can interact with the 
phosphatidylcholine headgroup of the membranes thereby possibly lowering the dipole potential 
of the lipid bilayer and hence enhancing drug permeation. 
 
The observed increase in electrical conductivity of the stratium corneum of the skin and blood 
brain barrier upon ultrasound treatment is an important factor which determines the transient 
permeabilization enhancement of drugs. It is likely that the dipole moment of permeating drugs 
may be a critically important factor that interacts with the membrane dipole potential of the 
stratium corneum of the skin and blood brain barrier upon ultrasound treatment. Transient pores 
are known to be involved when electrical fields are exerted on biological membranes, with 
conductance spikes occurring during the opening and closing of these transient pores. The 
opening and closing of lipidic pores also involve electrically invisible (silent) pre-pores.  
 
 
Experimental 
All calculations were carried out using the Gaussian 09 package. Energy optimizations were at 
the DFT/B3LYP/6-31G(d) (6d, 7f) level of theory for all atoms. Selected optimizations at the 
DFT/B3LYP/6-311G(d,p) (6d, 7f) level of theory gave very similar results to those at the lower 
level. Optimized structures were checked to ensure energy minima were located, with no 
negative frequencies. Energy calculations were conducted at the DFT/B3LYP/6-31G(d,p) (6d, 
7f) level of theory with optimized geometries in water, using the IEFPCM/SMD solvent model. 
With the 6-31G* basis set, the SMD model achieves mean unsigned errors of 0.6 - 1.0 kcal/mol 
in the solvation free energies of tested neutrals and mean unsigned errors of 4 kcal/mol on 
average for ions. [47] The 6-31G** basis set has been used to calculate absolute free energies of 
solvation and compare these data with experimental results for more than 500 neutral and 
charged compounds. The calculated values were in good agreement with experimental results 
across a wide range of compounds. [48,49] Adding diffuse functions to the 6-31G* basis set (ie 
6-31+G**) had no significant effect on the solvation energies with a difference of less than 1% 
observed in solvents, which is within the literature error range for the IEFPCM/SMD solvent 
model. HOMO and LUMO calculations included both delocalized and localized orbitals (NBO). 
 
Dextran (70kDa) and inulin (5kDa) in Table 1, were modeled with the notional C12 oligomer 
units of these biopolymers to compare ΔGdesolv,CDS, ΔGlipo,CDS, DM and MV values, assuming that 
the molecular properties of the full biopolymers would show comparative properties to the 
oligomer units. 
 
The QM calculations for DPhPC and mannitol or BCNU complexes used in Figures 2-4 were 
conducted at the DFT/B3LYP/6-31G(d,p) (6d, 7f) level of theory with MM optimized structures 
in water, using the IEFPCM/SMD solvent model. Using DFT/B3LYP/6-31G(d,p) (6d, 7f),  
DFT/B3LYP/6-311G(d,p) (6d, 7f) and DFT/B3LYP/6-31G(d)+ (6d, 7f) gave essentially the 
same results for the DM. Variation of the hydrogen bonding distances OH---OP, NH---OP, OH--
-O=C, and NH---O=C from 2.0-3.0Å had no effect on the overall DMs. The DM of DPhPC in 
water was 22.6D, while the ether-DPhPC (where the ester group of DPhPC as shown in Figure 1 
was replaced with an ether group) had a DM of 26.2DM. It is known that the ether-DPhPC 
membrane has a lower dipole potential than the ester-DPhPC membrane. [34] 
 
It is noted that high computational accuracy for each species in different environments is not the 
focus of this study, but comparative differences between various species is the aim of the study. 
The permeability values in Table 1 used to develop the multiple regression LFER equations have 
much higher experimental uncertainties than the QM calculated molecular properties. The 
statistical analyses include the multiple correlation coefficient R2, the F test of significance, 
standards errors for the estimates (SEE) and each of the variables SE(ΔGdesolCDS), SE(ΔGlipoCDS), 
SE(Dipole Moment), SE (Molecular Volume) as calculated from “t” distribution statistics. 
Residual analysis was used to identify outliers.  
 
 
 
 
 
Table 1  
 
Passive 
Permeability 
US Enhanced 
Permeability 
ΔGdesolv,CDS 
kcal/mol 
ΔGlipo,CDS 
kcal/mol 
Dipole 
Moment 
D 
Molec 
Volume 
cm3/mol 
Transdermal 
Drug Delivery 
Therapeutic 
US  
Benzene 160 1 -2.74 -3.43 0 78 
Butanol 2.2 1.5 -2.89 -2.45 2.25 68 
Caffeine 0.1 1.2 -4.87 -7.7 5.74 126 
Corticosterone 0.3 4 -7.7 -8.02 9.63 238 
Estradiol 3.2 13 -5.48 -7.62 4.15 208 
Progesterone 13 1 -7.5 -7.96 7.45 237 
Testosterone 2.2 5 -6.19 -7.39 4.94 251 
Transdermal 
Drug Delivery 
Low 
Frequency 
US 
Aldosterone 0.05 1400 -8.46 -8.45 8.66 291 
Butanol 2.2 29 -2.89 -2.45 2.25 68 
Salicyclic Acid 0.1 400 -5.19 -3.84 4.16 80 
Corticosterone 0.3 80 -7.7 -8.02 9.63 238 
Estradiol 3 3 -5.48 -7.62 4.15 208 
Sucrose 0.0052 5000 -6.72 -5.48 2.09 209 
Water 0.3 113 -1.46 -0.62 2.46 14 
BBB Drug 
Delivery 
Dextran C12 0.026 0.065 -6.32 -5.8 4.98 229 
Inulin C12 0.035 0.1 -7.22 -5.46 5.52 203 
Mannitol  0.55 4.71 -4.78 -3.34 3.16 114 
BCNU 0.28 0.76 -4.84 -4.44 3.66 125 
Water 8.42 29.4 -1.46 -0.62 2.46 14 
Notes:  
Transdermal passive and continuous US enhanced permeabilities are 10-3 cm/h, therapeutic US at 1 MHz, energy 
intensity up to 1W/cm2, low frequency US at 20-100 kHz, 0.84 W/cm2, data from refs 14-17 
Dextran 70 KDa was modeled with the nominal C12 polymer unit, and Inulin 5 KDa was modeled with the nominal 
C12 polymer unit; BBB permeability data are 10-5 cm/min, data from ref 18 
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Figure 1.  Top shows DPhPC (or ester-PHPC) with the main partial charges contributing to the 
dipole potential are shown as + and - on one chain of each lipid, Bottom shows ether-DPhPC 
where the ester group of DPhPC has been replaced by the ether group. Adapted from ref 34. 
 
 
    
 
Figure 2(a) left and 2(b) right:  left DPhPC (ester-DPhPC): DM 22.6D; black arrow showing 
dipole moment direction for DPhPC and phosphatidylcholine headgroup, red arrow showing 
dipole moment direction for ester group, and white arrow showing dipole potential direction for 
the DPhPC membrane with the potential being largest at the centre of the lipid bilayer of the 
membrane. Right ether-DPhPC 26.2DM black arrow showing dipole moment direction for 
DPhPC and phosphatidylcholine headgroup, and white arrow showing dipole potential direction 
for the ether-DPhPC membrane with the dipole potential being largest at the centre of the lipid 
bilayer of the membrane. 
 
     
 
Figure 3(a) left and 3(b) right: left DPhPC-Mannitol complex 25.9D, and right DPhPC-BCNU 
complex 21.3D, both drugs H bonded to the O atom of the phosphate P-O group of DPhPC 
 
    
Figure 4(a) left and 4(b) right: left DPhPC-Maanitol complex 23.2D, and right DPhPC-BCNU 
complex 23.7D, both drugs H bonded to the O atom of the ester C=O group of DPhPC 
 
